RICERCA
AUTORI
RIVISTE
Sfoglia per AUTORE
AURILIA C
Collezione ASL Asti
Items : 19
Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study. in Neurology and therapy / Neurol Ther. 2024 Oct;13(5):1505-1506. doi: 10.1007/s40120-024-00648-z.
2024
ASL Asti
Barbanti P; Egeo G; Proietti S; d'Onofrio F; Aurilia C; Finocchi C; Di Clemente L; Zucco M; Doretti A; Messina S; Autunno M; Ranieri A; Carnevale A; Colombo B; Filippi M; Tasillo M; Rinalduzzi S; Querzani P; Sette G; Forino L; Zoroddu F; Robotti M; Valenza A; Camarda C; Borrello L; Aguggia M; Viticchi G; Tomino C; Fiorentini G; et alii...
Correction to: Ultra-late response (>?24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study. in Journal of neurology / J Neurol. 2024 May;271(5):2444-2445. doi: 10.1007/s00415-024-12287-3.
2024
ASL Asti
Carnevale A; Robotti M; Salerno A; Grazzi L; Favoni V; di Poggio MLB; Colombo B; Cetta I; Di Clemente L; Zucco M; Orlando B; Fiorentini G; Cevoli S; Finocchi C; Trimboli M; Bertuzzo D; Aguggia M; Torelli P; D'Onofrio F; Proietti S; Egeo G; Aurilia C; Barbanti P; Frediani F; Altamura C; Filippi M; Vernieri F; Bonassi S;
Ultra-late response (>?24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study. in Journal of neurology / J Neurol. 2024 May;271(5):2434-2443. doi: 10.1007/s00415-023-12103-4. Epub 2024 Jan 17.
2024
ASL Asti
Carnevale A; Robotti M; Salerno A; Grazzi L; Favoni V; di Poggio MLB; Colombo B; Cetta I; Di Clemente L; Zucco M; Orlando B; Fiorentini G; Cevoli S; Finocchi C; Trimboli M; Bertuzzo D; Aguggia M; Torelli P; D'Onofrio F; Proietti S; Egeo G; Aurilia C; Barbanti P; Frediani F; Altamura C; Filippi M; Vernieri F; Bonassi S;
Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study. in Neurology and therapy / Neurol Ther. 2024 Jun;13(3):611-624. doi: 10.1007/s40120-024-00591-z. Epub 2024 Mar 7.
2024
ASL Asti
Borrello L; Aguggia M; Camarda C; Valenza A; Robotti M; Zoroddu F; Forino L; Sette G; Querzani P; Rinalduzzi S; Tasillo M; Filippi M; Colombo B; Carnevale A; Ranieri A; Autunno M; Messina S; Doretti A; Zucco M; Di Clemente L; Finocchi C; Aurilia C; d'Onofrio F; Proietti S; Egeo G; Barbanti P; Viticchi G; Tomino C; Fiorentini G; et alii...
2024
ASL Asti
Barbanti P; Aurilia C; Egeo G; Proietti S; D’Onofrio F; Torelli P; Aguggia M; Bertuzzo D; Finocchi C; Trimboli M; Cevoli S; Fiorentini G; Orlando B; Zucco M; Di Clemente L; Cetta I; Colombo B; di Poggio MLB; Favoni V; Grazzi L; Salerno A; Carnevale A; Robotti M; Frediani F; Altamura C; Filippi M; Vernieri F; Bonassi S;
2024
ASL Asti
Barbanti P; Aurilia C; Egeo G; Proietti S; D’Onofrio F; Torelli P; Aguggia M; Bertuzzo D; Finocchi C; Trimboli M; Cevoli S; Fiorentini G; Orlando B; Zucco M; Di Clemente L; Cetta I; Colombo B; di Poggio MLB; Favoni V; Grazzi L; Salerno A; Carnevale A; Robotti M; Frediani F; Altamura C; Filippi M; Vernieri F; Bonassi S;
Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study. in The journal of headache and pain / J Headache Pain. 2023 Mar 23;24(1):30. doi: 10.1186/s10194-023-01561-w.
2023
ASL Asti
Frediani F; Zoroddu F; Tasillo M; Aguggia M; Carnevale A; Colombo B; Autunno M; Sette G; Ranieri A; Di Clemente L; Rao R; Messina S; d'Onofrio L; d'Onofrio F; Finocchi C; Torelli P; Aurilia C; Egeo G; Barbanti P; Filippi M; Tomino C; Proietti S; Bonassi S;
Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT study. in European journal of neurology / Eur J Neurol. 2023 Jan;30(1):224-234. doi: 10.1111/ene.15563. Epub 2022 Sep 26.
2023
ASL Asti
Di Piero V; Albanese M; Ranieri A; Bono F; Aguggia M; Finocchi C; d'Onofrio L; Rao R; Maestrini I; Perrotta A; Favoni V; Lovati C; Egeo G; Aurilia C; Marcosano M; Brunelli N; Vernieri F; Cevoli S; Altamura C; Barbanti P;
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients. in The journal of headache and pain / J Headache Pain. 2022 Nov 1;23(1):138. doi: 10.1186/s10194-022-01498-6.
2022
ASL Asti
Bono F; Messina S; Fiorentini G; Carnevale A; Cevoli S; Messina R; Filippi M; Frediani F; Rao R; Zucco M; Albanese M; Aguggia M; Finocchi C; d'Onofrio F; Altamura C; Aurilia C; Egeo G; Barbanti P; Torelli P; Proietti S; Bonassi S; Vernieri F;
Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience. in Journal of neurology / J Neurol. 2022 Nov;269(11):5848-5857. doi: 10.1007/s00415-022-11226-4. Epub 2022 Jun 28.
2022
ASL Asti
Barbanti P; Di Piero V; Doretti A; Albanese M; Bono F; Messina R; Ranieri A; Finocchi C; Bertuzzo D; d'Onofrio F; Schiano Di Cola F; Maestrini I; Perrotta A; Lovati C; Favoni V; Egeo G; Marcosano M; Aurilia C; Cevoli S; Brunelli N; Altamura C; Vernieri F;
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study. in European journal of neurology / Eur J Neurol. 2022 Apr;29(4):1198-1208. doi: 10.1111/ene.15197. Epub 2021 Dec 6.
2022
ASL Asti
Cevoli S; Albanese M; Bono F; Colombo B; Ranieri A; Schiano Di Cola F; Finocchi C; Di Fiore P; Doretti A; Lovati C; Bertuzzo D; d'Onofrio F; Favoni V; Fofi L; Egeo G; Aurilia C; Costa CM; Barbanti P; Brunelli N; Altamura C; Vernieri F;
2022
ASL Asti
Barbanti P; Vernieri F; Aurilia C; Trimboli M; Di Clemente L; Zucco M; Bertuzzo D; Brunelli N; Costa C; Finocchi C; Di Fiore P; Favoni V; Aguggia M; Grazzi L; D'Onofrio F; Mercuri B; Frediani F; Colombo B; Altamura C; Filippi M; D'Amico D; Bono F; Carnevale A; Albanese M; Torelli P; Salerno A; Messina R; Cevoli S; Fiorentini G; et alii...
Late response to anti-CGRP (calcitonin gene-related peptide) monoclonal antibodies: implication for clinical practice in European Journal of Neurology
2022
AOU Città della Salute di Torino
ASL Asti
Aurilia C; Egeo G; Fiorentini G; Cevoli S; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Altamura C; Colombo B; Frediani F; Mercuri B; D'Onofrio F; Grazzi L; Aguggia M; Finocchi C; Di Fiore P; Zucco M; Trimboli M; Bonassi S; Vernieri F; Barbanti P;
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study) in Journal of Headache and Pain
2021
ASL Asti
Alfieri G; Manzo L; Pascarella A; Baldi O; Di Cola FS; Messina S; Trogu F; Frediani F; Capogrosso C; Bertuzzo D; Spitaleri D; Cevoli S; Barbanti P; Bono F; Ranieri A; Albanese M; Doretti A; Di Fiore P; Finocchi C; Rao R; Lovati C; Aguggia M; d’Onofrio F; Favoni V; Pierangeli G; Aurilia C; Egeo G; Fofi L; Vernieri F; et alii...
Long term (48-weeks) effectiveness, safety and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in real-world: The early 2 study in Journal of the Neurological Sciences
2021
ASL Asti
Salerno A; Torelli P; Albanese M; Egeo G; Fofi L; Messina R; Aurilia C; Cevoli S; Barbanti P; Trimboli M; Pascarella A; Manzo L; Bertuzzo D; Zucco M; Di Clemente L; Costa CM; Brunelli N; Fallacara A; Favoni V; Finocchi C; Di Fiore P; D'Onofrio F; Grazzi L; Aguggia M; Colombo B; Frediani F; Mercuri B; D'Amico D; Filippi M; et alii...
Long-term (>48 weeks) safety and tolerability of erenumab in real-life in Journal of the Neurological Sciences
2021
ASL Asti
Pascarella A; Manzo L; Barbanti P; Zucco M; Di Clemente L; Trimboli M; Costa CM; Brunelli N; Fallacara A; Bertuzzo D; Favoni V; Finocchi C; Fiore PD; Mercuri B; D'Onofrio F; Grazzi L; Aguggia M; Vernieri F; Colombo B; Frediani F; Bono F; D'Amico D; Filippi M; Altamura C; Torelli P; Albanese M; Carnevale A; Fofi L; Cevoli S; et alii...
Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study). in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology / Neurol Sci. 2020 Dec;41(Suppl 2):487-488. doi: 10.1007/s10072-020-04669-y.
2020
ASL Asti
ASL Vercelli
Frediani F; Cevoli S; Di Fiore P; Albanese M; Aguggia M; Bertuzzo D; Pierangeli G; Favoni V; Fallacara A; Costa CM; Fofi L; Egeo G; Barbanti P; Aurilia C; Brunelli N; Altamura C; Vernieri F;
New evidence from the italian chronic migraine registry (iron registry): An update on 866 patients in Neurology
2020
ASL Asti
Barbanti P; Fofi L; Egeo G; Aurilia C; Grazzi L; Vernieri F; Altamura C; Camarda C; Torelli P; Cevoli S; Russo A; Bono F; Finocchi C; Rao R; Messina S; De Simone R; D'Onofrio F; Aguggia M; Frediani F; Carnevale A; Autunno M; Lia C; Battista Allais G; Coppola A; Perini F; Balsamo P; Strumia S; Colombo B; Proietti S; et alii...
The Italian chROnic migraiNe (IRON) registry: First report from 28 headache centers in Journal of Headache and Pain
2018
ASL Asti
AOU Città della Salute di Torino
ASL Cuneo 2
ASL Torino 3
Barbanti P; Fofi L; Egeo G; Aurilia C; Cevoli S; Pierangeli G; Torelli P; Manzoni G; Camarda C; Grazzi L; D'Amico D; Vernieri F; Balsamo P; Frediani F; D'Arrigo G; Di Fiore P; Finocchi C; Perini F; D'Onofrio F; Bono F; Russo A; De Simone R; Ferra G; Busillo V; Carnevale A; Pierelli F; Di Lorenzo C; Valguarnera F; Rao R; et alii...